Anti-PD-L1 antibodies
US12209128B2 · kind B2 · utility
0Cited by
132References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 28, 2021 |
| Grant date | Jan 28, 2025 |
| Priority date | — |
| Expiry date | Nov 5, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/74
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.